Eli Lilly | LLY - Trade Creditors


Eli Lilly reported $5.79B in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Abbott USD 4.68B 439M Mar/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
AstraZeneca USD 23.57B 679M Sep/2026
Baxter International USD 1.02B 10M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Drreddys Laboratories INR 36.08B 13.72B Sep/2026
Eli Lilly USD 5.79B 319M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
GlaxoSmithKline GBP 15.63B 1.29B Sep/2026
Glaxosmithkline GBP 15.63B 1.3B Sep/2026
J&J USD 9.32B 94M Sep/2026
Medtronic USD 2.7B 51M Jun/2026
Merck USD 5.03B 1.2B Sep/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novartis USD 4.24B 15M Sep/2026
Novartis USD 4.24B 79M Sep/2026
Novo Nordisk DKK 14.59B 212M Jun/2026
Perrigo USD 390.5M 9.9M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Phibro Animal Health USD 136.45M 9.13M Sep/2026
Prestige Brands USD 44.02M 7.17M Sep/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sanofi EUR 24.55B 957M Sep/2026
Sanofi EUR 23.6B 888M Jun/2026
United Therapeutics USD 520.2M 22.4M Sep/2026
Zoetis USD 419M 33M Sep/2026